GPCR therapeutic monoclonal antibodies
SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.
SYnAbs discovers antibodies to transmembrane proteins including GPCR chemokine receptors thanks to unique peptide and cell immunization technologies
SYnAbs develops therapeutic monoclonal antibodies with agonistic or antagonistic effects to highly homologous G Protein-Coupled Receptors transmembrane proteins
SYnAbs unique therapeutic effector monoclonal antibodies targeting anaphylatoxin C3aR and C5aR GPCR. Functional antibody targeting complex transmembrane proteins and G protein-coupled receptors.
The Complement System and its druggable targets by antibodies: C3aR, C5aR GPCR membrane receptors, C3, C4, C5 ligands
Untapped therapeutic potential of orphan GPCR and SYnAbs functional monoclonals anti-GPCR. Generation of new antibody therapeutics targeting orphan membrane receptors.
SYnabs generate therapeutic monoclonal antibodies against CC chemokine receptors thanks to modified peptides, DNA and cell immunization strategies
SYnAbs develops anti-chemokine receptors monoclonal antibodies with therapeutic effect for Biotech and Pharma companies
Molecular dynamics of G protein-coupled receptors (GPCRs) and unique monoclonal antibody effectors and binders targeting GPCR.
SYnabs develops anti-GPCR stereo-specific monoclonal antibodies for Pharma and biotech companies thanks to unique proprietary DNA, peptide and cell immunization technologies